Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSR-042 as Maintenance Therapy for High-risk Locally Advanced Cervical Cancer (ATOMICC)
NCT03833479Phase 2Active, not recruiting
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
- Start
- Jun 2019
- Primary completion
- Jul 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of dostarlimab in Cervical Cancer (CC) (2 arms), sponsored by Grupo Español de Investigación en Cáncer de Ovario. Primary endpoint: Progression Free Survival at 30 months. Started Jun 2019; status: active, not recruiting.
02
Drugs
dostarlimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03833479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03833479.